Big Moving Stock chart patterns and volume.
The Hot Industries
Health Care Plans 3
Processed & Packaged Goods 2
Aerospace/Defense Products & Services 2
The Hot Sectors
Consumer Goods 4
CELG Celgene Corporation
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The companys commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The companys pre clinical and clinical stage products consist of OTEZLA for the treatment of psoriatic arthritis, psoriasis, and ankylosing spondylitis; CC-122 and CC-220 to treat hematological and solid tumor cancers; cellular therapies, such as PDA-001 and PDA-002 for Crohns and peripheral arterial diseases; CC-486, to treat MDS, AML, and solid tumors; Sotatercept and ACE-536 for the treatment of anemia in patients with rare blood disorders; CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers; and CC-292 for the treatment of chronic lymphocytic leukemia and lymphomas. It has strategic drug discovery collaboration with Abide Therapeutics to enhance the treatment paradigm for patients with immune disorders. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Stock Market News for March 30, 2015 - Market News30 Mar 2015, 8:10 amBenchmarks ended the last trading session of the week on a positive note after Fed Chair Janet Yellen said there was a possibility of a gradual hike in interest rates sometime this year
Stock Market Bulls Need to Step Up — or Else27 Mar 2015, 6:45 am© Richard Drew/AP Photo Traders at their post on the floor of the New York Stock Exchange. Stocks bounced off a key support level on Thursday in an attempt to put an end to three consecutive days of losses.
Celgene (CELG) Stock Declines Today as Bubble Fears Grow25 Mar 2015, 2:50 pmNEW YORK (TheStreet) -- Celgene shares closed trading down 4.21% to $117.01 on Wednesday as biotech stocks across the board were hit today as fears of an impending bubble in the sector rocked the NBI and smaller cap XBI ETFs today. The XBI -- SPDR S&P Biotech ETF fell 5% in trading today and has decreased 7% over the past five days, while the NBI ETF closed trading down 4.14% to $3,571.33.Fears ...
Stock Market News for March 24, 2015 - Market News24 Mar 2015, 8:10 amMarkets ended its choppy session in the red yesterday as fluctuations in the value of the U.S. dollar weighed on investor sentiment
CELG Stock - Here's Why Celgene Is Worth Snapping Up23 Mar 2015, 8:43 amCELG Stock - Here's Why Celgene Is Worth Snapping Up
Stock Market News for March 20, 2015 - Market News20 Mar 2015, 8:10 amBenchmarks finished mostly lower on Thursday after stronger US dollar adversely affected oil and other commodity prices, dragging down energy and material stocks
Critical Alerts For Celgene, Cliffs Natural Resources, Cintas, Workday and Isis Pharmaceuticals Released By ...19 Mar 2015, 7:46 amCHICAGO, March 19, 2015 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CELG, CLF, CTAS, WDAY and ISIS. To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Stock Market News for March 18, 2015 - Market News18 Mar 2015, 8:10 amBenchmarks finished mostly lower on Tuesday as investors grew jittery ahead of FOMC’s statement regarding rate hike
Celgene could be the next celgene9 Mar 2015, 6:15 amCelgene could be the next celgene
Celgene (CELG) Stock Gained Today on European Commission Approval of Revlimid9 Mar 2015, 3:10 amNEW YORK (TheStreet) -- Celgene shares closed trading up 2.68% to $123.43 in trading on Friday, nearing its all time high of $124.60, after the European Commission approved the use of the company's Revlimid (lenalidomide) treatment for adult patients with previously untreated multiple myeloma who are transplant ineligible. The news comes one day after the company announced that the FDA expanded ...